Previous 10 | Next 10 |
SOMERVILLE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class...
The microbiome is an exciting area of medical research that could help treat numerous medical problems such as Crohn's disease, Parkinson's and more. Finch Therapeutics is developing a treatment for C. difficile that was fast tracked by the FDA and is in Phase 3 trials. The compan...
SOMERVILLE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of ora...
Seth Klarman’s 13F portfolio value increased from $10.84B to $12.56B this quarter. Baupost Group increased Alphabet and Intel while reducing Fox Corp and dropping ViacomCBS. They also built small stakes in several SPACs. The portfolio continues to be heavily concentrated wi...
Finch Therapeutics (FNCH): Q1 GAAP EPS of -$1.00 misses by $0.74.Revenue of $3.55M (+98.3% Y/Y)Press Release For further details see: Finch Therapeutics EPS misses by $0.74
Completed upsized IPO, raising $130.8 million in gross proceeds Topline safety and efficacy data from more than 130 recurrent CDI patients treated with CP101 in PRISM-EXT expected in H2 2021 Strengthened leadership team with the appointment of Susan E. Graf to Board of D...
SOMERVILLE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of ora...
SOMERVILLE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of o...
SOMERVILLE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of o...
iRhythm continues to trade lower as analysts evaluate the impact of Novitas rate update on the company. Meanwhile, the recent FDA approvals have led Truist Securities to upgrade Bristol Myers.iRhythm downgraded at BTIG on uncertain outlookThe revision of Novitas reimbursement rates ...
News, Short Squeeze, Breakout and More Instantly...
Finch Therapeutics Group Inc. Company Name:
FNCH Stock Symbol:
NASDAQ Market:
Finch Therapeutics Group Inc. Website:
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 8.6% to $0.0384 on volume of 89,961,220 shares Nuburu Inc. (BURU) rose 29.4% to $0.207 on volume of 85,213,370 shares Novo Integrated Sciences Inc. (NVOS) rose 139.5% to $1.08 on volume ...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 5.3% to $0.0839 on volume of 148,968,464 shares Netcapital Inc. (NCPL) rose 66.0% to $0.2901 on volume of 111,713,040 shares Cue Health Inc. (HLTH) rose 33.6% to $0.126 on volume of 99,7...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...